Trial Profile
Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Talabostat (Primary)
- Indications Adenocarcinoma; Neuroendocrine carcinoma; Prostate cancer
- Focus First in man; Proof of concept; Registrational; Therapeutic Use
- Sponsors BioXcel Therapeutics
- 06 Jun 2023 Phase 2a activity threshold for accrual was met and Phase 2b portion of study was initiated to evaluate SCNC variant in a potential registrational randomized study.
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 22 May 2023 Status changed from recruiting to active, no longer recruiting.